JNJ-64619178 is under clinical development by Johnson & Johnson and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how JNJ-64619178’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
JNJ-64619178 is under development for the treatment of non-small cell lung cancer, small-cell lung cancer, relapsed/refractory B-cell non-Hodgkin lymphoma including diffuse large b-cell lymphoma, follicular lymphoma, mantle cell lymphoma, advanced solid tumors and lower risk myelodysplastic syndrome. The drug candidate is formulated as capsule and administered through oral route. It acts by targeting protein arginine N methyltransferase 5 (PRMT5).
Johnson & Johnson overview
Johnson & Johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular and metabolic diseases; consumer products in oral care, baby care, beauty, over-the-counter (OTC) medicines, women’s health and wound care categories; and medical devices for use in the cardiovascular, orthopaedic, general surgery and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and offers consumer products through retail outlets and distributors. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.
For a complete picture of JNJ-64619178’s drug-specific PTSR and LoA scores, buy the report here.